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Abstract
Background: Favorable clinical outcomes have been observed with glucose-insulin-potassium
infusion (GIK) in acute myocardial infarction (MI). The mechanisms of this beneficial effect have not
been delineated clearly. GIK has metabolic, anti-inflammatory and profibrinolytic effects and it may
preserve the ischemic myocardium. We sought to assess the effect of GIK infusion on infarct size
and left ventricular function, as part of a randomized controlled trial.
Methods: Patients (n = 940) treated for acute MI by primary percutaneous coronary intervention
(PCI) were randomized to GIK infusion or no infusion. Endpoints were the creatinine kinase MB-
fraction (CK-MB) and left ventricular ejection fraction (LVEF). CK-MB levels were determined 0,
2, 4, 6, 24, 48, 72 and 96 hours after admission and the LVEF was measured before discharge.
Results: There were no differences between the two groups in the time course or magnitude of
CK-MB release: the peak CK-MB level was 249 ± 228 U/L in the GIK group and 240 ± 200 U/L in
the control group (NS). The mean LVEF was 43.7 ± 11.0 % in the GIK group and 42.4 ± 11.7% in
the control group (P = 0.12). A LVEF ≤  30% was observed in 18% in the controls and in 12% of the
GIK group (P = 0.01).
Conclusion: Treatment with GIK has no effect on myocardial function as determined by LVEF and
by the pattern or magnitude of enzyme release. However, left ventricular function was preserved
in GIK treated patients.
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Background
It has been suggested that glucose-insulin-potassium
(GIK) infusion in acute myocardial infarction (MI) has
clinical benefit [1-4]. Both animal studies and early stud-
ies in patients to investigate the influence of GIK on inf-
arct size have shown conflicting results [5-14].
Experimental studies on the effect of GIK on preservation
of left ventricular function, as determined by hemody-
namic parameters, demonstrated a beneficial effect
[15,16]. Furthermore, in a small study in patients with
acute MI treated by thrombolysis, there was a significant
improvement in left ventricular function over a 10-day
period [17]. Recently, a small randomized trial of 37
patients has suggested that the addition of GIK to primary
percutaneous coronary intervention (PCI) has a beneficial
effect [18]. Large studies of GIK in the era of reperfusion
yielded some information about effects on myocardial
function [1,17,19]. The Polish Glucose-Insulin-Potassium
(Pol-GIK) trial with 954 patients, using low-dose GIK,
found no difference between median creatinine kinase
(CK) levels (920 IU/L in GIK patients versus 925 IU/L in
controls) [19]. Recently, in the REeValuation of Intensi-
fied Venous metabolic support for Acute infarct size Lim-
itation (REVIVAL) trial with 312 MI patients, the
combination of GIK and primary PCI had no effect on
myocardial salvage [20]. In the Glucose-Insulin-Potas-
sium Study (GIPS) with GIK infusion as adjunctive ther-
apy to primary PCI in acute MI, the 30-day mortality was
not significantly reduced in the overall population [4]. In
a predefined subgroup of patients without heart-failure at
admission, mortality was 1.2% in GIK patients versus
4.2% in controls (P = 0.01). In the present study we were
able to determine the effect of GIK on cumulative enzyme
release and left ventricular ejection fraction.
Methods
Study population
An outline of the study and 30-day clinical follow-up has
been reported [4]. All consecutive patients with symptoms
consistent with acute MI of >30 minutes duration, pre-
senting within 24 hours after the onset of symptoms and
with ST-segment elevation more than 1 mm (0.1 mV) in
two or more contiguous leads on the electrocardiogram,
were evaluated for inclusion in this study. Patients were
excluded if they had been pre-treated by thrombolysis or
when an illness associated with markedly restricted life
expectancy was present. Before randomization, age, gen-
der, history of coronary artery bypass grafting (CABG),
previous PCI, stroke and MI, existence of diabetes melli-
tus, smoking status, heart rate, arterial pressure, body
mass index, Killip class, electrocardiographic site of infarc-
tion, time of onset of symptoms, and time of hospital
admission in both the referring hospital and our hospital
were recorded. The research protocol was reviewed and
approved by the medical ethics committee of our hospi-
tal, and patients were included after informed consent.
Treatment protocol
Patients were randomly assigned to either GIK infusion or
no infusion. Assignments to the treatment groups were
made with the use of a computerized randomization pro-
gram. In the GIK group, a continuous infusion of 80
mmol potassium chloride in 500 mL 20% glucose was
given at a rate of 3 mL/kg/hour through a peripheral
venous line. A continuous infusion of short-acting insulin
(50 units Actrapid HM-Novo Nordisk, Copenhagen, Den-
mark) in 50 ml 0.9% sodium chloride was also initiated
using a pump (Perfusor-FM, B. Braun, Melsungen, Ger-
many). The baseline insulin-infusion dose and hourly
adjustments of the dose to obtain blood-glucose levels
between 7.0 and 11.0 mmol/l were determined using an
algorithm based on measurements of whole-blood glu-
cose concentration. The infusion was started as soon as
possible after randomization and continued for at least 8
hours with a maximum of 12 hours.
All patients went to the catheterization laboratory as soon
as possible after admission and randomization. In the lab-
oratory, both coronary arteries were visualized. PCI was
performed using standard techniques if the coronary anat-
omy was suitable for angioplasty. Additional treatment
consisted of unfractionated intravenous heparin, nitro-
glycerin and aspirin. After sheath removal, low-molecular-
weight heparin was given for 1 to 3 days. Before discharge,
additional pharmacological treatment consisting of aspi-
rin, clopidogrel, coumarins, beta-blockers, angiotensin-
converting enzyme inhibitors and statins was initiated
according to the guidelines of the American College of
Cardiology/American Heart Association. Enrollment of
patients began in April 1998 and ended in September
2001.
Measurements
Enzymatic infarct size was estimated by serial measure-
ments of the CK-MB fraction. The first measurement was
taken as soon as possible after admission. Thereafter fre-
quent CK-determinations were performed according to a
schedule that called for 4 to 8 measurements in the first 96
hours. To accommodate the problem that exact prede-
fined times for blood sampling were not always followed
in practice, the actual times of sampling were recorded,
expressed as minutes after the moment of randomization.
To allow optimal comparison of the time courses of CK-
MB levels and to best approximate the area under the CK-
MB curves, we developed an algorithm. This algorithm
estimated the time-course of CK-MB for each patient
before calculating the patient group means. According to
the known kinetics of CK-MB – a rapid rise and a much
slower decrease – the following characteristic time pointsBMC Medicine 2005, 3:9 http://www.biomedcentral.com/1741-7015/3/9
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with accompanying time intervals were defined: 0 h
(interval from 60 min before to 45 min after randomisa-
tion); 2 h (45 min to 3 h); 4 h (3 h to 5 h); 6 h (5 h to 12
h); 24 h (12 h to 36 h); 48 h (36 h to 60 h); 72 h (60 h to
84 h) and 96 h (84 h to 108 h). The algorithm interpo-
lated the CK-MB level for each patient based on the pre-
cise times at which the measurements were performed.
Next, it determined for each of the predefined intervals
whether an actual measurement had been performed in
that interval. If no measurement was available for a partic-
ular interval, a "not available" value was generated. This
avoided inappropriately interpolated values. If one or
more measurements were available for an interval, the
CK-MB value for the time point with the corresponding
interval was calculated from the area under the interpo-
lated curve divided by the interval duration. CK-MB was
determined enzymatically using a Hitachi 717 automatic
analyzer at 30 degrees Celsius according to the Interna-
tional Federation of Clinical Chemistry (IFCC) recom-
mendation. High enzyme release was defined as a peak
CK-MB above the 75% percentile (i.e. the highest quar-
tile). Time to peak CK-MB was determined.
Left ventricular ejection fraction (LVEF) was measured
before discharge by radionuclide ventriculography or by
echocardiography. Radionuclide ventriculography was
performed by the multiple gated equilibrium method fol-
lowing the labeling of the patient's red blood cells with
technetium 99mpertechnate. A General Electric 300
gamma camera with a low-energy all-purpose parallel-
hole collimator was used. The global ejection fraction was
calculated with a Star View computer (General Electric,
Wisconsin, USA) using the fully automatic PAGE pro-
gram. LVEF as assessed by two-dimensional transthoracic-
echocardiography was reported as a descriptive grade of
function, using subjective visual assessment by two inde-
pendent observers who were unaware of the randomisa-
tion code. This approach is less time-consuming than
other methods, such as Simpson's rule or wall motion
index score, but it can be at least as accurate as other meth-
ods [21]. Echocardiography was performed by observers
who were unaware of the randomization outcome and
clinical data. A LVEF ≤  30% was defined as a poor left ven-
tricular function before the analysis.
Statistical analysis
All analyses were by intention to treat. Predefined end-
points were pattern and magnitude of CK-MB release,
peak CK-MB, high enzyme release (defined as a peak
enzyme release in the highest quartile); mean LVEF, and a
LVEF lower than or equal to 30%. To allow comparison of
the patterns of CK-MB release, the CK-MB values 0, 2, 4,
6, 24, 48, 72 and 96 hours after admission were calculated
for each individual patient with linear interpolation. Dif-
ferences between group means were assessed with the
two-tailed Student's t-test. Chi-square analysis was used to
test differences between proportions. The Cox propor-
tional-hazards regression model was used to calculate rel-
ative risks adjusted for differences in baseline
characteristics. To predict the independent association
between treatment with GIK and a peak CK-MB release
above the highest quartile or LVEF ≤  30%, a multivariate
logistic regression analysis was performed. A two-tailed P
value <0.05 was considered statistically significant. The
Statistical Package for the Social Sciences (SPSS Inc., Chi-
cago, IL, USA) version 11.5 was used for all statistical
analyses.
Results
Study population
Of the 940 patients who underwent randomization, 476
were assigned to receive GIK infusion. There were no dif-
ferences in the baseline characteristics of the two treat-
ment groups table 1. The mean time between onset of
symptoms and admission was 150 min, and 75% of the
patients were admitted within 225 min. The interquartile
range (IQR) in the GIK group was 100 to 215 min and in
the control group 105 to 234 min. After coronary angiog-
raphy, 860 patients (90.5%) underwent PCI, 38 patients
(4%) were referred for CABG within 7 days, and 42
patients (4.5%) were treated conservatively. Thirty-day
mortality was 4.8% in the GIK patients and 5.8% in the
control patients [4].
Enzyme release
Data on the effect of GIK on enzymatic infarct size (CK-
MB) were available in 923 patients (98%), 470 patients
treated with GIK and 462 control patients. A mean of 6.9
CK-MB determinations per patient were available. As indi-
cated in figure 1, there was no difference in the pattern or
magnitude of CK-MB release between the two groups.
Mean peak CK-MB ± SD was 249 ± 228 U/L in the GIK
group and 240 ± 200 U/L in the control group (NS). In
GIK patients the median time to peak CK-MB was 450
min (IQR 300–733) compared to 468 min (IQR 285–
738) in the control patients (NS). High enzyme release
(i.e. peak CK-MB >349 U/L) was found in 111 patients
(24%) in the GIK group versus 121 patients (25%) in the
control group (P = 0.6). Differences between patients with
peak CK-MB release below and above 349 U/L are indi-
cated in table 2. Characteristics related to high enzyme
release were Killip class ≥  2, anterior MI and TIMI 0 flow
before PCI.
Left ventricular ejection fraction
LVEF measurements were available in 419 patients (88%)
treated with GIK and in 404 (87%) of the controls. Mean
time between admission and LVEF measurement was 2.65
days in the GIK group and 2.5 days in the control group
(IQR 2 days in both groups). The mean LVEF was 43.7 ±BMC Medicine 2005, 3:9 http://www.biomedcentral.com/1741-7015/3/9
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11.0 % in the GIK group and 42.4 ± 11.7% in the control
group (P = 0.12). Of the 823 patients with a measured
LVEF before discharge, a total of 125 (15%) had an ejec-
tion fraction lower than or equal to 30%. Differences
between patients with LVEF ≤  30% and those with a
higher LVEF are summarized in table 3. Treatment with
GIK was associated with a lower frequency of a LVEF ≤
30% (51 patients (12%) compared to 74 patients (18%),
P = 0.01). Other important characteristics associated with
LVEF ≤  30% were age, diabetes mellitus, Killip class, inf-
arct location and TIMI flow after PCI. To identify inde-
pendent predictors of a low left ventricular ejection
fraction (LVEF ≤  30%) all variables associated with LVEF
≤  30% in univariate analysis were used in multivariate
analysis; see table 3. After adjustment, patients treated
with GIK had a RR of 0.53 (95% confidence interval 0.35–
0.81, P = 0.01) for LVEF ≤  30% compared to controls. In
patients with Killip class 1 at admission the mean LVEF
was 44.1 ± 10.9 % in the GIK group versus 42.8 ± 11.5%
in the control group (P = 0.12). In these Killip class 1
patients randomized to GIK, a LVEF ≤  30% was less often
observed (45 patients (12%) versus 65 patients (17%), P
= 0.03).
In the overall population the mean peak CK-MB ± SD was
463 ± 318 U/L in patients with LVEF ≤  30% versus 215 ±
166 U/L in patients with LVEF >30% (P < 0.001).
Discussion
In this study, additional treatment with GIK in patients
treated with primary PCI for acute myocardial infarction
showed no decrease in enzymatic infarct size and no dif-
ference in mean LVEF between GIK and control patients
was observed. However, preservation of left ventricular
function as determined by a LVEF ≤  30% was more fre-
quently seen in GIK treated patients. One explanation for
the discrepancy between the effects on poor and mean left
ventricular function is that the number of patients in our
Table 1: Baseline clinical and demographic characteristics and initial therapies
Characteristics GIK group Control group
Age, years ± SD 60 ± 12 61 ± 12
Men 351 (73.7) 368 (79.3)
Referred patients 201 (42.3) 180 (38.8)
Body mass index 26.7 ± 3.8 27.0 ± 4.0
Previous MI 52 (10.9) 53 (11.4)
Previous PCI 22 (4.7) 24 (5.2)
Previous CABG 14 (2.9) 12 (2.6)
History of stroke 17 (3.6) 15 (3.2)
Diabetes mellitus 50 (10.5) 49 (10.6)
Hypertension 134 (28.2) 130 (28.0)
Dyslipidaemia 94 (19.7) 95 (20.5)
Currently smoker 225 (47.3) 237 (51.1)
Positive family history 195 (41.0) 179 (38.6)
Time to admission, min (IQR)* 150 (100–215) 150 (105–234)
Door to balloon time, min (IQR) 45 (31–64) 48 (34–69)
Killip class 1 426 (89.5) 430 (92.7)
Killip class 2 24 (5.0) 14 (3.0)
Killip class 3 14 (2.9) 14 (3.0)
Killip class 4 12 (2.5) 6 (1.3)
Anterior MI 250 (52.9) 224 (49.1)
Multi-vessel disease 249 (52.3) 242 (52.2)
PCI 436 (91.6) 424 (91.4)
Stent ** 255 (58.5) 236 (55.7)
GP IIb/IIIa receptor blocker ** 96 (22.1) 109 (25.7)
In-hospital CABG 19 (4.0) 19 (4.1)
TIMI 3 flow 459 (96.4) 435 (93.8)
Successful reperfusion‡ 394 (82.8) 384 (82.8)
Intra-aortic balloon pump 45 (9.5) 42 (9.1)
Mechanical ventilation 12 (2.5) 4 (0.9)
Data are numbers (%) unless otherwise indicated. MI = myocardial infarction. IQR = interquartile range. PCI = percutaneous coronary intervention. 
CABG = coronary artery bypass grafting. * Time to admission denotes time between onset of symptoms and admission. † In-hospital CABG = 
CABG defined as patients treated initially conservatively, followed by elective CABG within 7 days. ‡ Successful reperfusion denotes TIMI 3 flow 
and blush grade 2 or 3. ** Percentage defined as the percentage of the patients who underwent PCI.BMC Medicine 2005, 3:9 http://www.biomedcentral.com/1741-7015/3/9
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CK-MB release after admission in the GIK group and control group Figure 1
CK-MB release after admission in the GIK group and control group. CK-MB release after admission in the GIK group (unbro-
ken line) and control group (dashed line). Means are indicated for 0, 2, 4, 6, 24, 48, 72 and 96 hours. No significant difference 
was observed at any time point.
Table 2: Comparison of patients with a peak CK-MB release beneath the highest quartile and patients with a CK-MB release above the 
highest quartile
Characteristic High enzyme release (N = 232) Low enzyme release (N = 708) P-value
Age, years ± SD 59 ± 12 61 ± 12 0.17
Men 179 (77) 540 (76) 0.86
Hypertension 64 (28) 200 (28) 0.87
Previous MI 24 (10) 81 (11) 0.72
Diabetes mellitus 28 (12) 71 (10) 0.39
Killip class 1 192 (83) 664 (94) <0.001
Anterior MI 161 (69) 313 (44) <0.001
TIMI 0 before PCI 189 (82) 377 (53) <0.001
TIMI 3 after PCI 219 (94) 675 (95) 0.6
GIK treatment 121 (52) 355 (50) 0.6
Data are numbers (%) unless otherwise indicated. MI = myocardial infarction. TIMI = Thrombolysis in Myocardial Infarction. PCI = percutaneous 
coronary intervention.
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analysis was not sufficient to detect an effect on mean left
ventricular ejection fraction. Mean LVEF was 1.3% higher
in GIK patients, so and several patients may have been
prevented from LVEF ≤  30%.
Since these results are based on an intention-to-treat anal-
ysis in a randomized controlled trial of the effects of GIK,
we may have underestimated the effect on preservation of
myocardial function. In the control group more patients
died, and these patients had a high enzyme release and
probably a severely impaired LVEF as well. Nevertheless,
our data make it unlikely that GIK has a clinically relevant
impact of GIK on enzyme release, but at the same time
show an important reduction in the number of patients
with a LVEF ≤  30%. A LVEF ≤  30% exposes these patients
to a high risk of developing heart failure during follow-up,
even after successful PCI [22]. We also found a relation
between high enzyme release and poor left ventricular
function. Possibly the relation between GIK and poor
LVEF is related to a selection bias in this sub-analysis. On
the other hand it can be hypothesized that GIK mediates
effects on LVEF, as measured after 2 to 4 days after admis-
sion, that are unrelated to enzymatic infarct size.
In our previous study on the effect of GIK on 30-day mor-
tality, we found a beneficial effect of GIK on outcome in
patients who had no signs of heart-failure at admission.
Patients with Killip class 1 did not have smaller enzymatic
infarct sizes in this analysis. However, the CK-MB curve
over the first 96 hours after admission in GIK patients lies
below that in controls. Mean LVEF is higher in patients
treated with GIK compared to control patients, albeit not
significantly (P = 0.12). Even as in the overall population
in patients with Killip class 1 treatment with GIK was
related with a lower rate of LVEF ≤  30%.
Previous clinical studies with GIK
Several studies have reported enzymatic infarct size in MI
patients treated with GIK, mainly in patients without
reperfusion therapy [12,14]. Clinical studies in the era of
reperfusion provided sparse information [1,19]. In line
with our results, the Pol-GIK trial showed that neither the
median and maximal CK nor maximal glutamic-oxaloace-
tic transaminase differed significantly between GIK and
control patients [19]. However, the Pol-GIK trial used
low-dose GIK and included patients with a lower risk, i.e.
no patients with signs of heart failure were included. One
study of 32 MI patients treated by thrombolysis found
that infusion of GIK resulted in a shorter time to peak CK
and a smaller total enzyme release [6]. In line with our
results on enzyme release, the REVIVAL trial found no
effect of GIK treatment on the myocardial salvage index
measured with technetium-99m sestamibi scintigraphy
6 to 8 hours after admission and after 7 to 14 days (0.50
versus 0.48, P = 0.96). In this trial, GIK consisted of 1000
ml 20% glucose with 40 IU of insulin and 64 mmol potas-
sium chloride at a rate of 1.8 ml/hour for 24 hours. How-
ever, in the predefined subgroup of patients with diabetes
mellitus, a significant difference in salvage index was
found (mean difference 0.19, 95% confidence interval
0.01–0.37). In a trial of 37 patients treated with primary
PCI, a beneficial effect of GIK on myocardial function was
observed [18]. The increase of the LVEF from baseline to
3 months was 12.5% in the GIK group (P = 0.002) versus
6.1% in the placebo group (NS). However, when GIK and
placebo were compared directly, the difference between
increments in LVEF was not significant. This may have
been the result of a combination of small numbers of
patients and profound changes in the LVEF during the 3–
6 months after PCI for acute MI [23]. In patients with
diabetes mellitus and without myocardial ischemia, infu-
sion of insulin and glucose increased the contractile force,
i.e. rest LVEF and LVEF during dynamic exercise measured
Table 3: Comparison of patients with a low Left Ventricular Ejection Fraction (LVEF ≤  30%) with those with preserved Left Ventricular 
Ejection Fraction (LVEF >30%)
Characteristic Low LVEF (N = 125) Preserved LVEF (N = 698) P-value
Age, years ± SD 63 ± 12 59 ± 12 0.008
Men 98 (78) 537 (77) 0.7
Hypertension 43 (34) 182 (26) 0.05
Previous MI 18 (14) 63 (9) 0.06
Diabetes mellitus 29 (23) 57 (8) 0.008
Killip class 1 109 (87) 660 (95) 0.002
Anterior MI 115 (92) 291 (42) <0.001
TIMI 0 before PCI 40 (32) 291 (42) 0.04
TIMI 3 after PCI 114 (91) 677 (97) 0.002
GIK treatment 51 (41) 368 (53) 0.01
Data are numbers (%) unless otherwise indicated. MI = myocardial infarction. TIMI = Thrombolysis in Myocardial Infarction. PCI = percutaneous 
coronary intervention.BMC Medicine 2005, 3:9 http://www.biomedcentral.com/1741-7015/3/9
Page 7 of 10
(page number not for citation purposes)
by radionuclide ventriculography [24]. In 32 anterior MI
patients, the left ventricular wall motion score index as
measured by echocardiography at baseline was 1.87 and it
decreased significantly during GIK infusion to 1.76 (P <
0.001) [25].
In January 2005, the 30-day results of the Clinical Trial of
Reviparin and Metabolic Modulation in Acute Myocardial
Infarction Treatment Evaluation-Estudios Cardiologicos
Latinoamerica (CREATE-ECLA) trial (N = 20201) were
published [26]. Infusion of high-dose GIK had no benefi-
cial effect on the overall population, with a mortality rate
of 10.0% in the GIK group compared to 9.7% in the con-
trol group (P = 0.45). The lack of benefit was also
observed in several large subgroups that may benefit in
particular from GIK, such as patients treated within 4
hours after symptom onset (N = 8361). Only in patients
treated by PCI (N = 1838) was a reduction of 30-day mor-
tality observed, from 6.3% in control patients to 4.8% in
GIK patients; but this was not significant. Therefore, in
patients treated with a combination of GIK and reper-
fusion, as in our study, the role of metabolic modulation
in mortality and myocardial function needs further
investigation.
Animal studies
Several studies on animals have assessed the effects of GIK
on infarct size in myocardial infarction, but show conflict-
ing results [5,9,11]. A study of pigs showed that hearts
treated with GIK had significantly less tissue acidosis,
higher wall motion scores and less tissue necrosis [16].
Similar results were obtained in a study of rats, in which
the administration of GIK not only before induction of
ischemia but also during acute ischemia seemed benefi-
cial for myocardial function [10]. A recent study of dia-
betic sheep found that GIK improved left ventricular
contractility as determined by stroke work efficiency [27].
Mechanisms of action
We found a relationship between higher enzymatic infarct
size and low LVEF. Since we observed an effect of GIK only
on LVEF, the preservation of left ventricular function
could not be declared a reduction of myocardial necrosis.
The potential mechanisms by which GIK might be benefi-
cial include metabolic effects, direct hemodynamic
effects, improvement of coronary flow and catecho-
lamine-mediated effects. The main effect of GIK infusion
is supposed to be improved delivery of glucose to the
ischemic myocardium resulting in a suppression of free
fatty acids [28-31]. Treatment with glucose and insulin
inhibits lipolysis, thereby decreasing circulating free fatty
acid levels, and suppresses fatty acid oxidation. Moreover,
in the postischemic myocardium, contractile dysfunction
may also be caused by impairment of glucose oxidation
and cytosolic proton accumulation, so agents that
enhance glucose oxidation in the postischemic heart may
also improve contractile function [32]. After prolonged
periods of low-flow ischemia, functional recovery is
mainly determined by the extent of irreversible ischemic
damage. After brief episodes of ischemic damage, oxida-
tive metabolism rapidly returns, well before contractile
activity is restored. Therefore GIK treatment is likely to be
beneficial when started soon after the onset of ischemia.
Protection of ischemic cardiac cell membranes may also
improve reflow after reperfusion and protect against the
no-reflow phenomenon by reducing cell swelling and
microvascular compression [33]. These microvascular
protective effects on the coronary circulation are probably
similar in patients with and without diabetes mellitus
[34,35]. GIK infusion improved regional myocardial per-
fusion and function in segments adjacent to the infarct
area in patients recovering from an acute MI [36]. Another
beneficial mechanism may be the protective effect of GIK
on the cell membrane [37-39]. Insulin promotes toler-
ance against ischemic cell death via the activation of
innate cell-survival pathways in the heart [40]. However,
in a small study of patients with MI treated with PCI,
administration of GIK did not improve the enzymatic
antioxidant reserve [41].
Study limitations
Left ventricular function was measured in 88% of patients.
For some patients transferred back to the referring hospi-
tals within 48 hours the measurement was missing. The
same goes for patients who died within 48 hours. There-
fore the exact relation between LVEF and 30-day mortality
cannot be determined. It is unknown whether these miss-
ing data have influenced the results. We determined the
left ventricular function before discharge and it has been
suggested that measurements after long-term follow-up
are more predictive[18,23].
Conclusion
High-dose GIK infusion in patients with acute MI treated
with primary PCI had no effect on general left ventricular
function or the pattern and magnitude of enzyme release.
A lower rate of poor left ventricular function, defined as a
left ventricular ejection fraction ≤  30%, was observed in
GIK patients.
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CK-MB release after admission in the GIK group and control group of Killip class 1 patients Figure 2
CK-MB release after admission in the GIK group and control group of Killip class 1 patients. CK-MB release after admission in 
the GIK group (unbroken line) and control group (dashed line). Means are indicated for 0, 2, 4, 6, 24, 48, 72 and 96 hours. No 
significant difference was observed at any time point.
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